Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, ...
pharmaphorum3y
FDA clears Seagen, Genmab's Tivdak ADC for cervical cancer
Tivdak is a first-in-class therapy that combines an antibody target at tissue factor – a protein expressed on cervical cancer cells – with a cell-killing drug called monomethyl auristatin E.
Hosted on MSN2mon
Zai Lab to seek China approval for cervical cancer therapy after positive trial data
Based on topline data, ZLAB said Tivdak, an antibody-drug conjugate, cut mortality risk by 45% in Chinese patients who had previously received standard systemic therapies. The Shanghai-based ...
Nasdaq6d
Zai Lab : China Accepts TIVDAK BLA For Treatment Of Recurrent Or Metastatic Cervical Cancer
(RTTNews) - Zai Lab Limited (ZLAB) announced that China's National Medical Products Administration or NMPA has accepted the Biologics License Application or BLA for TIVDAK (tisotumab vedotin-tftv ...
Hosted on MSN1mon
Zai Labs announces positive results in China arm of Phase III cervical cancer trial
Chinese-American biopharmaceutical company Zai Lab has announced positive topline results from the China-specific arm in its Phase III innovaTV-301 study examining its antibody-drug conjugate (ADC ...
Nasdaq1mon
Genmab Publishes 2024 Annual Report
Net product sales and collaboration revenue growth is driven by strong performance for both EPKINLY and Tivdak. Net product sales and collaboration revenue consists of EPKINLY net product sales in ...
Business Wire6d
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
TIVDAK, the only antibody-drug conjugate (ADC) therapy in cervical cancer, demonstrated promising benefits including a clinically meaningful improvement in overall survival (OS) in the pivotal ...
Yahoo Finance5d
Zai Lab announces acceptance of BLA for TIVDAK in cervical cancer
Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License Application for TIVDAK, tisotumab vedotin-tftv, for the treatment of patients ...
Morningstar6d
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688 ...
Joplin Globe7d
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab ...